Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Inclusion Criteria:
Exclusion Criteria:
Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.
Sijsele-Damme, 8340, Belgium
Burbaby, British Columbia V5G 2X6, Canada
Ostrava-Poruba, 70852, Czechia
Homburg/Saar, 66421, Germany
Petofi, 2500, Hungary
Szentpeteri-Kapu, 3526, Hungary
Gallarte, 21013, Italy
Sittard-Geleen, 6162, Netherlands
Umed, 90185, Sweden
Devon, PL6 SBX, United Kingdom